Chairman of the Board
Tom E. Pike holds a number of board positions within the life science industry. Previous positions includes Partner in the venture capital fund NeoMed, Chairperson & CEO of Clavis Pharma ASA as well as Chairperson of the Association of the Pharmaceutical Industry in Norway. He has also worked at Hoffman-La Roche in Norway and Switzerland for 18 years, including 8 years as general manager in Norway. Other current assignments include: Chairperson at Kaydence AS and Credio AS, board member at Photocure ASA, Vectron Biosolutions AS, Vingmed Holding AS. He is also Associate Professor at OsloMet University as well as strategy council member of HelseOmsorg21, a Norwegian government strategy program. Mr Pike holds a B.Sc. Honours in Pharmacology.
Erlend Skagseth is Managing Partner of early stage Venture funds Sarsia Seed I & II. Through these Funds he has been in involved in investments in 17 early stage Life Science companies. He has more than 30 years of experience from R&D, project- and business development and finance both as CEO, CFO and from numerous board positions, amongst others currently Chairman of Apim Therapeutics AS and Board member of Coegin Pharma AB. He holds an MBA from The Norwegian School of Economics.
Ingrid Alfheim, PhD, has for the last 15 years been the CEO of Bio-Medisinsk Innovasjon AS, a serial founder of biomedical companies including Vaccibody AS. She has more than 20 years experience in basic and applied research within toxicology and biomedicine. Before her current position, she held the position as CSO of a biotech start-up company Euromed AS and as director of R&D in the diagnostic company Axis-Shield (which was later acquired by Alere, and then by Abbott), where she was heading research groups in Norway, Scotland and in the US. She has been a board member of several public research institutions as well as of biotech start-ups and listed companies. She has worked for the Research Council of Norway in charge of Norway’s participation in the pan European research programme Eureka. Dr. Alfheim is currently chairing the board of Oslo Quartet Series, in addition to her participation in the board of young biomedical companies.
Anders Tuv is Investment Director at early stage life science investment company Radforsk with a focus on immunotherapies and precision medicines. He is an experienced investment and business development professional with broad experience from the health care and biotech industry covering management positions, strategy and business development, research collaborations, licensing deals, M&As and IPOs. He has extensive experience with establishing and developing early stage biotech companies, as well as fundraising and private placements as an investor. Anders has also been heavily involved in the development of a sound Norwegian Biotech Cluster through initiatives such as the Oslo Cancer Cluster and as one of the founders of Oslo Cancer Cluster Incubator.
He holds several Chairman and Non-executive director positions in Norwegian biotech Companies.
Bernd R. Seizinger, M.D., Ph.D. has been Chairman of Opsona Therapeutics Ltd. since 2009 and was Interim CEO/Executive Chairman of Opsona in 2011-2013.
Dr. Bernd R. Seizinger, M.D., Ph.D. is currently Chairman/Board member of a number of public and private biotech companies in the U.S., Canada and Europe, including Oxford BioTherapeutics, Aprea, CryptoMedix, Vaccibody and Oncolytics. In addition, he is on the Advisory Board of Pureos Ventures (BB Biotech/Bank Bellevue, Zurich) and Senior Advisor to Hadean Ventures (Stockholm, Oslo).
Dr. Seizinger was President & Chief Executive Officer of GPC Biotech (Princeton, NJ, Cambridge, MA, Munich, Germany), Executive Vice President and Chief Scientific Officer of Genome Therapeutics Corporation (Waltham/Boston, MA), Vice President of Oncology Drug Discovery and – in parallel – Vice President of Corporate and Academic Alliances at Bristol-Myers Squibb (BMS) in Princeton, NJ, USA.
Prior to his corporate appointments, Dr. Seizinger held Senior Faculty positions at Harvard Medical School, Massachusetts General Hospital and Princeton University.
He has authored more than 100 publications, including a number of papers in Nature, Science and Cell, and has been the recipient of numerous scientific Awards.
Lars Lund-Roland has a marketing and business background and works today as a business and management consultant. He is among others the business lead in Norway for Scandinavian Development Services AB, a Nordic multi-disciplinary strategic drug and medical device development company out of Stockholm, Sweden. Lars has been Managing Director of MSD Norway (Merck & Co Inc. subsidiary) for 10 years and has more than twenty-five years’ experience from various executive positions within marketing and sales at Merck as well as CEO of Bringwell AB(pub), a Nordic health and welfare company listed in Stockholm, that commercializes OTC pharmaceuticals, nutrition and food supplements. He also serves as Chairman of the Board of The Norwegian Life Science Cluster and has served as board member of Infodoc AS and Health Tech AS, two Norwegian health technology companies, as well as on the board of Targovax ASA and the Norwegian Association of Pharmaceutical Manufacturers.
Jan Haudemann-Andersen holds a siviløkonom-business degree from BI Norwegian Business School. He has extensive investment experience from private and listed companies in Norway and abroad. Mr. Haudemann-Andersen is sole owner of Datum and Datum invest and a shareholder of Vaccibody.
Susanne Stuffers holds an M.D. degree from the Erasmus University Rotterdam (Netherlands) and a Ph.D. degree in cancer biomedicine from the Norwegian Radiumhospital. She has experience from management consultancy in health care and life sciences at EY (2014 – 2015), from medical and commercial roles in the pharmaceutical industry (Novartis, 2011 – 2014), and from clinical practice as a resident in oncology (OUS Ullevål, 2010-2011). Susanne worked with Arctic Securities as an equity analyst covering the healthcare sector (2015-2018) and is currently CEO/partner of P53 Invest AS, an investment company with sole focus on healthcare investments.